Ascendis Pharma A/S - Ordinary Share (ASND) closed at $252.73 on November 20, 2026, down 1.3% from the previous close, on volume of 486,946 shares (30-day average 678,577).
Data as of November 20, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 13, 2026 | Strap Strangle | 19-Mar-27200 P : 330[1.25x] C | 900 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
Citi Sticks to Their Buy Rating for Ascendis Pharma (ASND)
TipRanks (Mon, 16-Nov 2:35 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: Twist Bioscience (TWST), Ascendis Pharma (ASND)
TipRanks (Sun, 15-Nov 8:20 PM ET)
Ascendis Pharma Earnings Call Signals Strong Growth Ahead
TipRanks (Sun, 15-Nov 12:03 AM ET)
Ascendis Pharma Reports Third Quarter 2026 Financial Results
Globe Newswire (Thu, 12-Nov 7:30 AM ET)
Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
Globe Newswire (Tue, 10-Nov 4:01 PM ET)
Globe Newswire (Fri, 6-Nov 8:00 AM ET)
Globe Newswire (Thu, 5-Nov 4:01 PM ET)
Globe Newswire (Mon, 26-Oct 8:00 AM ET)
Globe Newswire (Fri, 16-Oct 8:29 AM ET)
Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
Globe Newswire (Tue, 6-Oct 9:15 AM ET)
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Ascendis Pharma A/S - Ordinary Share trades on the NASDAQ stock market under the symbol ASND.
As of November 20, 2026, ASND stock price declined to $252.73 with 486,946 million shares trading.
ASND has a beta of 0.35, meaning it tends to be less sensitive to market movements. ASND has a correlation of 0.01 to the broad based SPY ETF.
ASND has a market cap of $16.58 billion. This is considered a Large Cap stock.
Last quarter Ascendis Pharma A/S - Ordinary Share reported $425 million in Revenue and $1.97 earnings per share. This beat revenue expectation by $8 million and exceeded earnings estimates by $.84.
In the last 3 years, ASND traded as high as $282.15 and as low as $90.13.
The top ETF exchange traded funds that ASND belongs to (by Net Assets): TCAF, IBB, IWP, IWR, IWF.
ASND has outperformed the market in the last year with a price return of +19.1% while the SPY ETF gained +5.2%. ASND has also outperformed the stock market ETF in the last 3 month and 2 week periods returning -2.7% and -0.3%, respectively, while the SPY returned -10.1% and -5.9%, respectively.
ASND support price is $250.87 and resistance is $261.05 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ASND shares will trade within this expected range on the day.